// App-Quantinova.ai

4501 : Association between depth of response (DepOR) and clinical outcomes Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

Researchers

Presenter

  • Cristina Suárez

Principal Investigators

  • Toni K. Choueiri

  • Mauricio Burotto

  • Thomas Powles

  • Maria Teresa Bourlon

  • Amishi Yogesh Shah

  • Yoshihiko Tomita

  • Jens Bedke

  • Joshua Zhang

  • Burcin Simsek

  • Christian Scheffold

  • Bernard Escudier

  • Robert J. Motzer

  • Andrea B. Apolo

Medical Centers

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Bradford Hill Research Center, Santiago, Chile

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

  • Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

  • 1.MD Anderson Cancer Center, Houston, TX

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • Eberhard Karls University, Tubingen, Germany

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Exelixis, Alameda, CA

  • Gustave Roussy, Villejuif, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Locations

  • Spain

  • United States

  • Chile

  • United Kingdom

  • Mexico

  • Japan

  • Germany

  • France

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT03141177

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved